PDT Partners’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $554K | Sell |
25,470
-80,016
| -76% | -$1.55M | 0.03% | 411 |
|
|
2025
Q4 | $2.27M | Sell |
105,486
-10,760
| -9% | -$227K | 0.15% | 231 |
|
|
2025
Q3 | $2.24M | Hold |
116,246
| – | – | 0.14% | 239 |
|
|
2025
Q2 | $1.99M | Buy |
116,246
+62,465
| +116% | +$2.66M | 0.11% | 301 |
|
|
2025
Q1 | $3.43M | Buy |
53,781
+38,033
| +242% | +$4M | 0.24% | 132 |
|
|
2024
Q4 | $1.91M | Sell |
15,748
-23,276
| -60% | -$2.85M | 0.17% | 212 |
|
|
2024
Q3 | $4.87M | Buy |
39,024
+3,795
| +11% | +$525K | 0.43% | 32 |
|
|
2024
Q2 | $5.57M | Buy |
35,229
+4
| +0% | +$514 | 0.53% | 19 |
|
|
2024
Q1 | $4.56M | Hold |
35,225
| – | – | 0.43% | 40 |
|
|
2023
Q4 | $3.4M | Buy |
+35,225
| New | +$3.38M | 0.38% | 59 |
|
|
2023
Q2 | – | Sell |
-8,900
| Closed | -$1.23M | – | 647 |
|
|
2023
Q1 | $1.23M | Buy |
+8,900
| New | +$1.15M | 0.17% | 217 |
|
|
2022
Q4 | – | Sell |
-15,006
| Closed | -$1.66M | – | 879 |
|
|
2022
Q3 | $1.66M | Sell |
15,006
-18,012
| -55% | -$1.82M | 0.25% | 92 |
|
|
2022
Q2 | $2.48M | Sell |
33,018
-41,977
| -56% | -$3.09M | 0.22% | 123 |
|
|
2022
Q1 | $5.86M | Buy |
74,995
+16,528
| +28% | +$1.27M | 0.5% | 19 |
|
|
2021
Q4 | $5.26M | Buy |
58,467
+8,924
| +18% | +$763K | 0.4% | 38 |
|
|
2021
Q3 | $4.58M | Sell |
49,543
-13
| -0% | -$1K | 0.33% | 107 |
|
|
2021
Q2 | $3.85M | Buy |
49,556
+22,756
| +85% | +$1.73M | 0.25% | 192 |
|
|
2021
Q1 | $2M | Buy |
+26,800
| New | +$2.47M | 0.14% | 267 |
|
|
2019
Q1 | – | Sell |
-113,400
| Closed | -$12.4M | – | 494 |
|
|
2018
Q4 | $12.4M | Sell |
113,400
-117,200
| -51% | -$14.7M | 0.69% | 30 |
|
|
2018
Q3 | $37.2M | Sell |
230,600
-21,879
| -9% | -$2.99M | 1.55% | 4 |
|
|
2018
Q2 | $33.4M | Sell |
252,479
-163,109
| -39% | -$15.4M | 1.27% | 6 |
|
|
2018
Q1 | $30.8M | Sell |
415,588
-149,965
| -27% | -$10M | 1.04% | 6 |
|
|
2017
Q4 | $31.5M | Buy |
+565,553
| New | +$30M | 0.91% | 18 |
|
|
2017
Q2 | – | Sell |
-338,997
| Closed | -$10M | – | 567 |
|
|
2017
Q1 | $10M | Buy |
+338,997
| New | +$10.5M | 0.53% | 40 |
|
|
2015
Q4 | – | Sell |
-288,429
| Closed | -$9.26M | – | 890 |
|
|
2015
Q3 | $9.26M | Buy |
288,429
+212,610
| +280% | +$7.21M | 0.21% | 129 |
|
|
2015
Q2 | $2.31M | Buy |
+75,819
| New | +$1.55M | 0.06% | 382 |
|
|
2013
Q4 | – | Sell |
-89,651
| Closed | -$4.23M | – | 1104 |
|
|
2013
Q3 | $4.23M | Sell |
89,651
-46,222
| -34% | -$1.78M | 0.11% | 227 |
|
|
2013
Q2 | $5.17M | Buy |
+135,873
| New | +$4.86M | 0.13% | 191 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
PDT Partners's SRPT Position: Q1 2026 in Review
PDT Partners reduced its Sarepta Therapeutics (SRPT) stake by 76% in Q1 2026, selling an estimated $1.55M and leaving 25,470 shares worth $554K. The position accounts for 0.03% of the portfolio, ranked #411.
PDT Partners first reported a position in SRPT in Q2 2013 and has held it in 28 quarters since. The position peaked at $37.2M in Q3 2018. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- PDT Partners held 25,470 shares of Sarepta Therapeutics worth $554K as of Q1 2026.
- PDT Partners sold 80,016 Sarepta Therapeutics shares in Q1 2026, an estimated $1.55M.
- Sarepta Therapeutics made up 0.03% of PDT Partners's portfolio in Q1 2026, its #411 holding.
- PDT Partners first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 28 quarters since.
- PDT Partners's Sarepta Therapeutics position peaked at $37.2M in Q3 2018.
- 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.